Edwards Lifesciences stock launched higher Thursday after the medtech company beat Wall Street's top- and bottom-line ...

July 23 (Reuters) - Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped ...

Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare sentiment remain in focus.

Edwards Lifesciences struck an upbeat tone on its latest earnings call, pointing to double‑digit sales growth, expanding margins and a strengthened outlook for 2026. Management acknowledged currency ...

Training camp is underway for the Los Angeles Rams and so is the latest awareness push from one of the franchise’s healthcare partners, Edwards Lifesciences. The medtech company unveiled the full ...

(RTTNews) - Edwards Lifesciences Corp. (EW) on Tuesday said its SAPIEN M3 mitral valve replacement system received U.S. Food and Drug Administration (FDA) approval for the treatment of mitral ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences said it has secured FDA approval for the first surgical valve replacement designed for patients with ...

Around 12 million Americans are affected by heart valve disease but an estimated 75% of people are unaware of the condition, which creates a need for greater awareness about the condition. To elevate ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S.

Reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10% Advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025: TAVR growth ...

Well, good morning, everyone. We really appreciate you all joining us today. Thank you for making the trip out here. For those of you who are in person. I'm Mark Wilterding, SVP of Global Finance and ...